The prevalence of superficial fungal infections across the globe is increasing from 20-25%. Superficial infections are mostly caused by dermatophytes. Depending on the site affected, the dermatophytes are clinically classified as Tinea capitis (head), Tinea faciei (face), Tinea barbae (beard), Tinea manus (hand), Tinea corporis (body), Tinea cruris (groin), Tinea pedis (foot), and Tinea unguium (nail).

TAKE HOME MESSAGE

This current study aims to evaluate the effectiveness of luliconazole in real-world settings. In the present study, 1% luliconazole was prescribed for four weeks maybe due to the prolonged duration of the infections as most of the patients had complaints of infections for 4-5 weeks or more.

Topical therapy is an accepted method of treatment for superficial infections caused by dermatophytes. Oral agents are reserved for severe or recalcitrant cases.

The topical application of azole antifungal agents has been proved as an effective treatment.

Newer therapy aimed at antifungals with a longer duration of action and once daily dosing is recommended.

Longer duration of treatment with old generation topical antifungal agents usually triggers the patient non-adherence which in turn raises the chances of disease relapse.

Luliconazole, an antifungal agent, has shown promising results in clinical trials within short duration of treatment has greater patient compliance and is effective for treatment of Tinea pedis, Tinea cruris, and Tinea corporis caused by T. rubrum and E. floccosum

In the current study, the infections were mainly Tinea cruris and Tinea corporis. A complete clearance (mycological cure and clinical cure) in 95% patients marked the recovery.

Luliconazole demonstrated effectiveness in the treatment of Tinea corporis, Tinea cruris and Tinea pedis.